Search

Your search keyword '"Claar, Ernesto"' showing total 126 results
Start Over Author "Claar, Ernesto"
126 results on '"Claar, Ernesto"'

1. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

Author

Aghemo, Alessio, Baiguera, Chiara, Battezzati, Pier Maria, Battistella, Sara, Bavetta, Maria Grazia, Bertoni, Costanza, Boni, Carolina, Brambilla, Paola, Bray, Antonella, Briano, Federica, Carmenini, Enrico, Castelli, Francesco, Cavalletto, Luisa, Cerini, Federica, Chidichimo, Luciana, Colella, Elisa, Cologni, Giuliana, Como, Silvia, Corsini, Romina, Costa, Chiara, Cotugno, Rosa, Cretella, Silvia, De Angelis, Fernando, De Leo, Pasqualina, Perri, Giovanni Di, Falbo, Elisabetta, Ferrigno, Luigina, Fornasiere, Ezio, Francisci, Daniela, Gatti, Pietro, Lampertico, Pietro, Lenci, Ilaria, Licata, Anna, Maida, Ivana, Marzano, Alfredo, Mastroianni, Antonio, Mazzaro, Cesare, Monti, Monica, Nardone, Gerardo, Nicolini, Laura Ambra, Passigato, Nicola, Pasticci, Maria Bruna, Pierotti, Piera, Pinchera, Biagio, Pollicino, Teresa, Porcu, Carmen, Quartini, Giulia, Rancatore, Gabriele, Romeo, Mario, Rumi, Maria Grazia, Saracino, Annalisa, Schioppa, Ornella, Serio, Ilaria, Soffredini, Roberta, Tata, Xhimi, Tizzani, Marco, Tonnini, Matteo, Torti, Carlo, Valenti, Daniela, Zaltron, Serena, Zoncada, Alessia, Kondili, Loreta A., Brancaccio, Giuseppina, Tosti, Maria Elena, Coco, Barbara, Quaranta, Maria Giovanna, Messina, Vincenzo, Ciancio, Alessia, Morisco, Filomena, Cossiga, Valentina, Claar, Ernesto, Rosato, Valerio, Ciarallo, Marianna, Cacciola, Irene, Ponziani, Francesca Romana, Cerrito, Lucia, Coppola, Roberta, Longobardi, Francesco, Biliotti, Elisa, Rianda, Alessia, Barbaro, Francesco, Coppola, Nicola, Stanzione, Maria, Barchiesi, Francesco, Fagiuoli, Stefano, Viganò, Mauro, Massari, Marco, Russo, Francesco Paolo, Ferrarese, Alberto, Laccabue, Diletta, Di Marco, Vito, Blanc, Pierluigi, Marrone, Aldo, Morsica, Giulia, Federico, Alessandro, Ieluzzi, Donatella, Rocco, Alba, Foschi, Francesco Giuseppe, Soria, Alessandro, Chessa, Luchino, Milella, Michele, Rosselli Del Turco, Elena, Madonia, Salvatore, Chemello, Liliana, Gentile, Ivan, Toniutto, Pierluigi, Bassetti, Matteo, Surace, Lorenzo, Baiocchi, Leonardo, Pellicelli, Adriano, De Santis, Adriano, Puoti, Massimo, Degasperi, Elisabetta, Niro, Grazia Anna, Zignego, Anna Linda, Craxi, Antonio, Raimondo, Giovanni, Santantonio, Teresa Antonia, Brunetto, Maurizia Rossana, and Gaeta, Giovanni Battista

Published
2024
Full Text
View/download PDF

2. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

Author

Pasulo, Luisa, Coppola, Carmine, Pisano, Federica, Romano, Mariarosaria, Porcu, Carmen, Bottalico, Irene Francesca, Cossiga, Valentina, Tata, Xhimi, Sagnelli, Caterina, Pierotti, Piera, Degasperi, Elisabetta, Rosato, Valerio, Badia, Lorenzo, Ieluzzi, Dontella, Monti, Monica, Bavetta, Maria Grazia, Cavalletto, Luisa, Toniutto, Pierluigi, Fornasiere, Ezio, Colecchia, Antonio, Ferrarese, Alberto, Nardone, Gerardo, Rocco, Alba, Viganò, Mauro, Foschi, Francesco Giuseppe, Conti, Fabio, Morsica, Giulia, Salpietro, Stefania, Torti, Carlo, Costa, Chiara, Federico, Alessandro, Dallio, Marcello, Giorgini, Alessia, Anselmo, Marco, De Leo, Pasqualina, Zaltron, Serena, Cambianica, Anna, Piscaglia, Fabio, Serio, Ilaria, Schivazappa, Simona, Mastroianni, Antonio, Chidichimo, Luciana, Massari, Marco, Mazzaro, Cesare, Marrone, Aldo, D'Amore, Francesca Maria, D'Offizi, Gianpiero, Licata, Anna, Niro, Grazia Anna, Pollicino, Teresa, Aghemo, Alessio, Brancaccio, Giuseppina, Coco, Barbara, Nardi, Alessandra, Quaranta, Maria Giovanna, Tosti, Maria Elena, Ferrigno, Luigina, Cacciola, Irene, Messina, Vincenzo, Chessa, Luchino, Morisco, Filomena, Milella, Michele, Barbaro, Francesco, Ciancio, Alessia, Russo, Francesco Paolo, Coppola, Nicola, Blanc, Pierluigi, Claar, Ernesto, Verucchi, Gabriella, Puoti, Massimo, Zignego, Anna Linda, Chemello, Liliana, Madonia, Salvatore, Fagiuoli, Stefano, Marzano, Alfredo, Ferrari, Carlo, Lampertico, Pietro, Di Marco, Vito, Craxì, Antonio, Santantonio, Teresa Antonia, Raimondo, Giovanni, Brunetto, Maurizia R., Gaeta, Giovanni Battista, and Kondili, Loreta A.

Published
2023
Full Text
View/download PDF

3. WED-446 Safety of direct-acting antivirals for hepatitis C infection and direct oral anticoagulants co-administration: an italian multicentric study

Author

Rosato, Valerio, primary, Dallio, Marcello, additional, Spinetti, Angiola, additional, Ciancio, Alessia, additional, Milella, Michele, additional, Colombatto, Piero, additional, D'Adamo, Giuseppe, additional, Del Turco, Elena Rosselli, additional, Gallo, Paolo, additional, Pugliese, Nicola, additional, D'Ambrosio, Roberta, additional, Colella, Elisa, additional, Brunetto, Maurizia, additional, Falcomatà, Andrea, additional, Vespasiani-Gentilucci, Umberto, additional, De Nicola, Stella, additional, Aghemo, Alessio, additional, Lampertico, Pietro, additional, Soria, Alessandro, additional, Izzi, Antonio, additional, Federico, Alessandro, additional, Mastrocinque, Davide, additional, and Claar, Ernesto, additional

Published
2024
Full Text
View/download PDF

4. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort

Author

Kondili, Loreta A., primary, Brancaccio, Giuseppina, additional, Tosti, Maria Elena, additional, Coco, Barbara, additional, Quaranta, Maria Giovanna, additional, Messina, Vincenzo, additional, Ciancio, Alessia, additional, Morisco, Filomena, additional, Cossiga, Valentina, additional, Claar, Ernesto, additional, Rosato, Valerio, additional, Ciarallo, Marianna, additional, Cacciola, Irene, additional, Ponziani, Francesca Romana, additional, Cerrito, Lucia, additional, Coppola, Roberta, additional, Longobardi, Francesco, additional, Biliotti, Elisa, additional, Rianda, Alessia, additional, Barbaro, Francesco, additional, Coppola, Nicola, additional, Stanzione, Maria, additional, Barchiesi, Francesco, additional, Fagiuoli, Stefano, additional, Viganò, Mauro, additional, Massari, Marco, additional, Russo, Francesco Paolo, additional, Ferrarese, Alberto, additional, Laccabue, Diletta, additional, Marco, Vito Di, additional, Blanc, Pierluigi, additional, Marrone, Aldo, additional, Morsica, Giulia, additional, Federico, Alessandro, additional, Ieluzzi, Donatella, additional, Rocco, Alba, additional, Foschi, Francesco Giuseppe, additional, Soria, Alessandro, additional, Maida, Ivana, additional, Chessa, Luchino, additional, Milella, Michele, additional, Turco, Elena Rosselli del, additional, Madonia, Salvatore, additional, Chemello, Liliana, additional, Gentile, Ivan, additional, Toniutto, Pierluigi, additional, Bassetti, Matteo, additional, Surace, Lorenzo, additional, Baiocchi, Leonardo, additional, Pellicelli, Adriano, additional, De Santis, Adriano, additional, Puoti, Massimo, additional, Degasperi, Elisabetta, additional, Niro, Grazia Anna, additional, Zignego, Anna Linda, additional, Craxi, Antonio, additional, Raimondo, Giovanni, additional, Santantonio, Teresa Antonia, additional, Brunetto, Maurizia Rossana, additional, Gaeta, Giovanni Battista, additional, and Investigators, on behalf of PITER Collaborating, additional

Published
2024
Full Text
View/download PDF

5. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

Author

D’Amato, Daphne, De Vincentis, Antonio, Malinverno, Federica, Viganò, Mauro, Alvaro, Domenico, Pompili, Maurizio, Picciotto, Antonino, Palitti, Valeria Pace, Russello, Maurizio, Storato, Silvia, Pigozzi, Marie Graciella, Calvaruso, Vincenza, De Gasperi, Elisabetta, Lleo, Ana, Castellaneta, Antonino, Pellicelli, Adriano, Cazzagon, Nora, Floreani, Annarosa, Muratori, Luigi, Fagiuoli, Stefano, Niro, Grazia Anna, Feletti, Valentina, Cozzolongo, Raffaele, Terreni, Natalia, Marzioni, Marco, Pellicano, Rinaldo, Pozzoni, Pietro, Baiocchi, Leonardo, Chessa, Luchino, Rosina, Floriano, Bertino, Gaetano, Vinci, Maria, Morgando, Anna, Vanni, Ester, Scifo, Gaetano, Sacco, Rodolfo, D’Antò, Maria, Bellia, Valentina, Boldizzoni, Roberto, Casella, Silvia, Omazzi, Barbara, Poggi, Guido, Cristoferi, Laura, Gerussi, Alessio, Ronca, Vincenzo, Venere, Rosanna, Ponziani, Francesca, Cannavò, Maria, Mussetto, Alessandro, Fontana, Rosanna, Losito, Francesco, Frazzetto, Evelise, Distefano, Marco, Colapietro, Francesca, Labanca, Sara, Marconi, Giulia, Grassi, Giuseppe, Galati, Giovanni, O’Donnell, Sarah Elizabeth, Mancuso, Clara, Mulinacci, Giacomo, Palermo, Andrea, Claar, Ernesto, Izzi, Antonio, Picardi, Antonio, Invernizzi, Pietro, Carbone, Marco, and Vespasiani-Gentilucci, Umberto

Published
2021
Full Text
View/download PDF

6. Analysis of Patients’ Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C: A Real-World Retrospective Italian Analysis

Author

Nava, Felice Alfonso, primary, Mangia, Alessandra, additional, Riglietta, Marco, additional, Somaini, Lorenzo, additional, Foschi, Francesco Giuseppe, additional, Claar, Ernesto, additional, Maida, Ivana, additional, Ucciferri, Claudio, additional, Frigerio, Francesca, additional, Hernandez, Candido, additional, Dovizio, Melania, additional, Perrone, Valentina, additional, Degli Esposti, Luca, additional, and Puoti, Massimo, additional

Published
2023
Full Text
View/download PDF

7. Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma

Author

Nevola, Riccardo, primary, Tortorella, Giovanni, additional, Rosato, Valerio, additional, Rinaldi, Luca, additional, Imbriani, Simona, additional, Perillo, Pasquale, additional, Mastrocinque, Davide, additional, La Montagna, Marco, additional, Russo, Antonio, additional, Di Lorenzo, Giovanni, additional, Alfano, Maria, additional, Rocco, Maria, additional, Ricozzi, Carmen, additional, Gjeloshi, Klodian, additional, Sasso, Ferdinando Carlo, additional, Marfella, Raffaele, additional, Marrone, Aldo, additional, Kondili, Loreta Anesti, additional, Esposito, Nicolino, additional, Claar, Ernesto, additional, and Cozzolino, Domenico, additional

Published
2023
Full Text
View/download PDF

8. Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy

Author

Pandico, Fulvio, primary, Citarella, Anna, additional, Cammarota, Simona, additional, Bernardi, Francesca Futura, additional, Claar, Ernesto, additional, Coppola, Carmine, additional, Cozzolino, Marianna, additional, De Rosa, Federica, additional, Di Gennaro, Massimo, additional, Fogliasecca, Marianna, additional, Giordana, Roberta, additional, Pacella, Daniela, additional, Russo, Alessandro, additional, Salerno, Vito, additional, Scafa, Luca, additional, and Trama, Ugo, additional

Published
2023
Full Text
View/download PDF

9. Predicting de‐novoportal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort

Author

Kondili, Loreta A., Zanetto, Alberto, Quaranta, Maria Giovanna, Ferrigno, Luigina, Panetta, Valentina, Calvaruso, Vincenza, Zignego, Anna Linda, Brunetto, Maurizia R., Raimondo, Giovanni, Biliotti, Elisa, Ieluzzi, Donatella, Iannone, Andrea, Madonia, Salvatore, Chemello, Liliana, Cavalletto, Luisa, Coppola, Carmine, Morisco, Filomena, Barbaro, Francesco, Licata, Anna, Federico, Alessandro, Cerini, Federica, Persico, Marcello, Pompili, Maurizio, Ciancio, Alessia, Piscaglia, Fabio, Chessa, Luchino, Giacometti, Andrea, Invernizzi, Pietro, Brancaccio, Giuseppina, Benedetti, Antonio, Baiocchi, Leonardo, Gentile, Ivan, Coppola, Nicola, Nardone, Gerardo, Craxì, Antonio, Russo, Francesco Paolo, Monti, Monica, Coco, Barbara, Filomia, Roberto, Bruno, Erica Maria, Cossiga, Valentina, Amodeo, Simona, Dallio, Marcello, Crapanzano, Luciano, Masarone, Mario, De Siena, Martina, Serio, Ilaria, Loi, Martina, Brescini, Lucia, Ciaccio, Antonio, Cucco, Monica, Tata, Xhimi, Sagnelli, Caterina, Sgamato, Costantino, Claar, Ernesto, Rosselli Del Turco, Elena, Rumi, Maria Grazia, Gaeta, Giovanni Battista, and Simioni, Paolo

Abstract

Sustained virological response (SVR) by direct‐acting antivirals (DAAs) may reverse the hypercoagulable state of HCV cirrhosis and the portal vein thrombosis (PVT) risk. We evaluated the incidence and predictive factors of de novo, non‐tumoral PVT in patients with cirrhosis after HCV eradication. Patients with HCV‐related cirrhosis, consecutively enrolled in the multi‐center ongoing PITER cohort, who achieved the SVR using DAAs, were prospectively evaluated. Kaplan‐Meier and competing risk regression analyses were performed. During a median time of 38.3 months (IQR: 25.1–48.7 months) after the end of treatment (EOT), among 1609 SVR patients, 32 (2.0%) developed de novo PVT. A platelet count ≤120,000/μL, albumin levels ≤3.5 mg/dL, bilirubin >1.1 mg/dL, a previous liver decompensation, ALBI, Baveno, FIB‐4, and RESIST scores were significantly different (p< 0.001), among patients who developed PVT versus those who did not. Considering death and liver transplantation as competing risk events, esophageal varices (subHR: 10.40; CI 95% 4.33–24.99) and pre‐treatment ALBI grade ≥2 (subHR: 4.32; CI 95% 1.36–13.74) were independent predictors of PVT. After HCV eradication, a significant variation in PLT count, albumin, and bilirubin (p< 0.001) versus pre‐treatment values was observed in patients who did not develop PVT, whereas no significant differences were observed in those who developed PVT (p> 0.05). After the EOT, esophageal varices and ALBI grade ≥2, remained associated with de novo PVT (subHR: 9.32; CI 95% 3.16–27.53 and subHR: 5.50; CI 95% 1.67–18.13, respectively). In patients with HCV‐related cirrhosis, a more advanced liver disease and significant portal hypertension are independently associated with the de novo PVT risk after SVR.

Published
2024
Full Text
View/download PDF

10. Efficacy and safety of lusutrombopag in a real-world Italian series of cirrhotic patients with severe thrombocytopenia undergoing invasive procedures: the Reality study

Author

Gallo, Paolo, primary, De Vincentis, Antonio, additional, Palitti, Valeria Pace, additional, Russello, Maurizio, additional, Vignone, Anthony, additional, Alvaro, Domenico, additional, Tortora, Raffaella, additional, Biolato, Marco, additional, Pompili, Maurizio, additional, Calvaruso, Vincenza, additional, Veneziano, Marzia, additional, Rosato, Valerio, additional, Claar, Ernesto, additional, Villani, Rosanna, additional, Izzi, Antonio, additional, Cozzolongo, Raffaele, additional, Distefano, Marco, additional, Messina, Vincenzo, additional, Ragone, Enrico, additional, Sacco, Rodolfo, additional, Cacciatore, Pierluigi, additional, Moretti, Alessandra, additional, Terracciani, Francesca, additional, Picardi, Antonio, additional, and Gentilucci, Umberto Vespasiani, additional

Published
2023
Full Text
View/download PDF

11. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?

Author

Nevola, Riccardo, primary, Delle Femine, Augusto Delle, additional, Rosato, Valerio, additional, Kondili, Loreta Anesti, additional, Alfano, Maria, additional, Mastrocinque, Davide, additional, Imbriani, Simona, additional, Perillo, Pasquale, additional, Beccia, Domenico, additional, Villani, Angela, additional, Ruocco, Rachele, additional, Criscuolo, Livio, additional, La Montagna, Marco La, additional, Russo, Antonio, additional, Marrone, Aldo, additional, Sasso, Ferdinando Carlo, additional, Marfella, Raffaele, additional, Rinaldi, Luca, additional, Esposito, Nicolino, additional, Barberis, Giuseppe, additional, and Claar, Ernesto, additional

Published
2023
Full Text
View/download PDF

12. HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis

Author

Nevola, Riccardo, primary, Beccia, Domenico, additional, Rosato, Valerio, additional, Ruocco, Rachele, additional, Mastrocinque, Davide, additional, Villani, Angela, additional, Perillo, Pasquale, additional, Imbriani, Simona, additional, Delle Femine, Augusto, additional, Criscuolo, Livio, additional, Alfano, Maria, additional, La Montagna, Marco, additional, Russo, Antonio, additional, Marfella, Raffaele, additional, Cozzolino, Domenico, additional, Sasso, Ferdinando Carlo, additional, Rinaldi, Luca, additional, Marrone, Aldo, additional, Adinolfi, Luigi Elio, additional, and Claar, Ernesto, additional

Published
2023
Full Text
View/download PDF

13. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

Author

Brancaccio, Giuseppina, primary, Coco, Barbara, additional, Nardi, Alessandra, additional, Quaranta, Maria Giovanna, additional, Tosti, Maria Elena, additional, Ferrigno, Luigina, additional, Cacciola, Irene, additional, Messina, Vincenzo, additional, Chessa, Luchino, additional, Morisco, Filomena, additional, Milella, Michele, additional, Barbaro, Francesco, additional, Ciancio, Alessia, additional, Russo, Francesco Paolo, additional, Coppola, Nicola, additional, Blanc, Pierluigi, additional, Claar, Ernesto, additional, Verucchi, Gabriella, additional, Puoti, Massimo, additional, Zignego, Anna Linda, additional, Chemello, Liliana, additional, Madonia, Salvatore, additional, Fagiuoli, Stefano, additional, Marzano, Alfredo, additional, Ferrari, Carlo, additional, Lampertico, Pietro, additional, Di Marco, Vito, additional, Craxì, Antonio, additional, Santantonio, Teresa Antonia, additional, Raimondo, Giovanni, additional, Brunetto, Maurizia R., additional, Gaeta, Giovanni Battista, additional, Kondili, Loreta A., additional, Pasulo, Luisa, additional, Coppola, Carmine, additional, Pisano, Federica, additional, Romano, Mariarosaria, additional, Porcu, Carmen, additional, Bottalico, Irene Francesca, additional, Cossiga, Valentina, additional, Tata, Xhimi, additional, Sagnelli, Caterina, additional, Pierotti, Piera, additional, Degasperi, Elisabetta, additional, Rosato, Valerio, additional, Badia, Lorenzo, additional, Ieluzzi, Dontella, additional, Monti, Monica, additional, Bavetta, Maria Grazia, additional, Cavalletto, Luisa, additional, Toniutto, Pierluigi, additional, Fornasiere, Ezio, additional, Colecchia, Antonio, additional, Ferrarese, Alberto, additional, Nardone, Gerardo, additional, Rocco, Alba, additional, Viganò, Mauro, additional, Foschi, Francesco Giuseppe, additional, Conti, Fabio, additional, Morsica, Giulia, additional, Salpietro, Stefania, additional, Torti, Carlo, additional, Costa, Chiara, additional, Federico, Alessandro, additional, Dallio, Marcello, additional, Giorgini, Alessia, additional, Anselmo, Marco, additional, De Leo, Pasqualina, additional, Zaltron, Serena, additional, Cambianica, Anna, additional, Piscaglia, Fabio, additional, Serio, Ilaria, additional, Schivazappa, Simona, additional, Mastroianni, Antonio, additional, Chidichimo, Luciana, additional, Massari, Marco, additional, Mazzaro, Cesare, additional, Marrone, Aldo, additional, D'Amore, Francesca Maria, additional, D'Offizi, Gianpiero, additional, Licata, Anna, additional, Niro, Grazia Anna, additional, Pollicino, Teresa, additional, and Aghemo, Alessio, additional

Published
2023
Full Text
View/download PDF

14. Analysis of Patients’ Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C: A Real-World Retrospective Italian Analysis

Author

Nava,Felice Alfonso, Mangia,Alessandra, Riglietta,Marco, Somaini,Lorenzo, Foschi,Francesco Giuseppe, Claar,Ernesto, Maida,Ivana, Ucciferri,Claudio, Frigerio,Francesca, Hernandez,Candido, Dovizio,Melania, Perrone,Valentina, Degli Esposti,Luca, Puoti,Massimo, Nava,Felice Alfonso, Mangia,Alessandra, Riglietta,Marco, Somaini,Lorenzo, Foschi,Francesco Giuseppe, Claar,Ernesto, Maida,Ivana, Ucciferri,Claudio, Frigerio,Francesca, Hernandez,Candido, Dovizio,Melania, Perrone,Valentina, Degli Esposti,Luca, and Puoti,Massimo

Abstract

Felice Alfonso Nava,1 Alessandra Mangia,2 Marco Riglietta,3 Lorenzo Somaini,4 Francesco Giuseppe Foschi,5 Ernesto Claar,6 Ivana Maida,7 Claudio Ucciferri,8 Francesca Frigerio,9 Candido Hernandez,10 Melania Dovizio,11 Valentina Perrone,11 Luca Degli Esposti,11 Massimo Puoti12 1U.O. Sanità Penitenziaria e Area Dipendenze, Azienda ULSS 6 Euganea, Padova, Italy; 2UOS Epatologia, Istituto di Ricovero e Cura “Casa Sollievo della Sofferenza”, S. Giovanni Rotondo, Italy; 3UOC Dipendenze, ASST Papa Giovanni XXIII, Bergamo, Italy; 4Servizio per le Dipendenze, SERT di Cossato, Biella, Italy; 5UOC Medicina Interna, Ospedale di Faenza, Faenza, Italy; 6UOC Medicina Interna, Ospedale Evangelico “Villa Betania”, Napoli, Italy; 7UOC Malattie Infettive e Parassitarie, Azienda Ospedaliero Universitaria di Sassari, Sassari, Italy; 8Clinica di Malattie Infettive Ospedale “SS Annunziata”, Chieti, Italy; 9Gilead Sciences, Milano, Italy; 10Gilead Sciences, Global Medical Affairs, Stockley Park, London, UB11 1BD, UK; 11CliCon S.R.L. Società Benefit, Health Economics and Outcomes Research, Bologna, Italy; 12SC Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milano, ItalyCorrespondence: Luca Degli Esposti, CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Via Murri, 9, Bologna, 40137, Italy, Tel +39 544 38393, Fax +39 544 212699, Email luca.degliesposti@clicon.itPurpose: Hepatitis C virus (HCV) spreads from contact with blood of an infected person. HCV infections are common among people who use drugs (PWUDs), when sharing needles, syringes, or other equipment for injected drugs. The advent of pangenotypic direct-antiviral agents (DAA) in 2017 transformed the treatment landscape for HCV, but PWUDs remain a complex and hard-to-treat population with high risk of HCV reinfection. The aim of this real-world analysis was to characterize the demographic and clinical features of PWUDs in Italy, also focusing on comorbidity profile, treatment wit

Published
2023

15. Predictors of early and late hepatocellular carcinoma recurrence

Author

Nevola, Riccardo, primary, Ruocco, Rachele, additional, Criscuolo, Livio, additional, Villani, Angela, additional, Alfano, Maria, additional, Beccia, Domenico, additional, Imbriani, Simona, additional, Claar, Ernesto, additional, Cozzolino, Domenico, additional, Sasso, Ferdinando Carlo, additional, Marrone, Aldo, additional, Adinolfi, Luigi Elio, additional, and Rinaldi, Luca, additional

Published
2023
Full Text
View/download PDF

17. Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies

Author

Nevola, Riccardo, primary, Rosato, Valerio, additional, Conturso, Vincenza, additional, Perillo, Pasquale, additional, Le Pera, Teresa, additional, Del Vecchio, Ferdinando, additional, Mastrocinque, Davide, additional, Pappalardo, Annalisa, additional, Imbriani, Simona, additional, Delle Femine, Augusto, additional, Piacevole, Alessia, additional, and Claar, Ernesto, additional

Published
2022
Full Text
View/download PDF

18. Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic

Author

Rosato, Valerio, primary, Nevola, Riccardo, additional, Conturso, Vincenza, additional, Perillo, Pasquale, additional, Mastrocinque, Davide, additional, Pappalardo, Annalisa, additional, Le Pera, Teresa, additional, Del Vecchio, Ferdinando, additional, and Claar, Ernesto, additional

Published
2022
Full Text
View/download PDF

20. Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology?

Author

Nevola, Riccardo, primary, Messina, Vincenzo, additional, Marrone, Aldo, additional, Coppola, Nicola, additional, Rescigno, Carolina, additional, Esposito, Vincenzo, additional, Sangiovanni, Vincenzo, additional, Claar, Ernesto, additional, Pisaturo, Mariantonietta, additional, Fusco, Francesco Maria, additional, Rosario, Pietro, additional, Izzi, Antonio, additional, Pisapia, Raffaella, additional, Rosato, Valerio, additional, Maggi, Paolo, additional, and Adinolfi, Luigi Elio, additional

Published
2022
Full Text
View/download PDF

22. TOP-085 Final results from the italian real-world experience on lusutrombopag treatment in cirrhotic patients with severe thrombocytopenia: insights from the reality study

Author

Gallo, Paolo, De Vincentis, Antonio, Pace Palitti, Valeria, Russello, Maurizio, Vignone, Anthony, Alvaro, Domenico, Tortora, Raffaella, biolato, marco, Pompili, Maurizio, Calvaruso, Vincenza, Veneziano, Marzia, Tizzani, Marco, Frigo, Francesco, Caneglias, Alessandro, Marcantonio, Gesualdo, Marzano, Alfredo, Rosato, Valerio, Claar, Ernesto, Villani, Rosanna, Izzi, Antonio, Cozzolongo, Raffaele, Airoldi, Aldo, Mazzarelli, Chiara, Distefano, Marco, Iegri, Claudia, Fagiuoli, Stefano, Messina, Vincenzo, Ragone, Enrico, Sacco, Rodolfo, Cacciatore, Pierluigi, Masutti, Flora, Saveria Crocè, Lory, Moretti, Alessandra, Terracciani, Francesca, Falcomata, Andrea, Di Pasquale, Giulia, Flagiello, Valentina, Picardi, Antonio, and Vespasiani-Gentilucci, Umberto

Published
2024
Full Text
View/download PDF

23. Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study

Author

Rosato, Valerio, primary, Ascione, Antonio, additional, Nevola, Riccardo, additional, Fracanzani, Anna Ludovica, additional, Piai, Guido, additional, Messina, Vincenzo, additional, Claar, Ernesto, additional, Coppola, Carmine, additional, Fontanella, Luca, additional, Lombardi, Rosa, additional, Staiano, Laura, additional, Valente, Giovanna, additional, Fascione, Maria Chiara, additional, Giorgione, Chiara, additional, Mazzocca, Annalisa, additional, Galiero, Raffaele, additional, Perillo, Pasquale, additional, Marrone, Aldo, additional, Sasso, Ferdinando Carlo, additional, Adinolfi, Luigi Elio, additional, and Rinaldi, Luca, additional

Published
2021
Full Text
View/download PDF

24. Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients

Author

Gerussi, A, Rigamonti, C, Elia, C, Cazzagon, N, Floreani, A, Pozzi, R, Pozzoni, P, Claar, E, Pasulo, L, Fagiuoli, S, Cristoferi, L, Carbone, M, Invernizzi, P, Gerussi, Alessio, Rigamonti, Cristina, Elia, Chiara, Cazzagon, Nora, Floreani, Annarosa, Pozzi, Roberta, Pozzoni, Pietro, Claar, Ernesto, Pasulo, Luisa, Fagiuoli, Stefano, Cristoferi, Laura, Carbone, Marco, Invernizzi, Pietro, Gerussi, A, Rigamonti, C, Elia, C, Cazzagon, N, Floreani, A, Pozzi, R, Pozzoni, P, Claar, E, Pasulo, L, Fagiuoli, S, Cristoferi, L, Carbone, M, Invernizzi, P, Gerussi, Alessio, Rigamonti, Cristina, Elia, Chiara, Cazzagon, Nora, Floreani, Annarosa, Pozzi, Roberta, Pozzoni, Pietro, Claar, Ernesto, Pasulo, Luisa, Fagiuoli, Stefano, Cristoferi, Laura, Carbone, Marco, and Invernizzi, Pietro

Abstract

Chronic immunosuppression is associated with increased and more severe viral infections. However, little is known about the association between immunosuppression and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our aim was to describe the clinical course of patients with immunosuppressed autoimmune hepatitis (AIH) during coronavirus disease 2019 (COVID-19) infection in Italy. Our study is a case series of patients with AIH treated with immunosuppression, who tested positive for SARS-CoV-2 in March 2020 during the outbreak of COVID-19. Ten patients from seven different hospitals in Italy were diagnosed with COVID-19 during the outbreak of SARS-CoV-2 in March 2020. Seven subjects were female (70%), and age ranged from 27 to 73 years. Before the onset of SARS-CoV-2 infection, all patients were taking immunosuppressive therapy for AIH, and eight of them were on biochemical remission. Two other patients had recent acute onset of their AIH, and consequently started high-dose steroids, as per induction protocol. All patients had a respiratory syndrome and a positive nasal swab for SARS-CoV-2. Five patients developed a computed tomography-confirmed COVID-19 pneumonia. Six subjects received a combination of antiretroviral and antimalarial drugs. In seven patients, the dosage of immunosuppressive medication was changed. Liver enzymes were repeated during SARS-CoV-2 infection in all hospitalized cases; they remained within the normal range in all cases, and improved in the two acute cases treated with high-dose steroids. The clinical outcome was comparable to the reported cases occurring in non-immunosuppressed subjects.Conclusion:Patients under immunosuppressive therapy for AIH developing COVID-19 show a disease course presumptively similar to that reported in the non-immunosuppressed population. These data might aid in medical decisions when dealing with SARS-CoV-2 infection in immunocompromised patients.

Published
2020

25. Factors Enhancing Treatment of Hepatitis C Virus–Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience

Author

Rinaldi, Luca, primary, Messina, Vincenzo, additional, Di Marco, Vito, additional, Iovinella, Vincenzo, additional, Claar, Ernesto, additional, Cariti, Giuseppe, additional, Sacco, Rodolfo, additional, De Luca, Massimo, additional, Scifo, Gaetano, additional, Gatti, Pietro, additional, Barbarini, Giorgio, additional, Pace Palitti, Valeria, additional, Quartini, Mariano, additional, Tundo, Paolo, additional, D'Offizi, Gianpiero, additional, Parruti, Giustino, additional, di Rosolini, Maria Antonietta, additional, Garrucciu, Giovanni, additional, Cosco, Lucio, additional, Benanti, Francesco, additional, Gimignani, Giancarlo, additional, Vespasiani Gentilucci, Umberto, additional, Di Lorenzo, Francesco, additional, D'Antò, Maria, additional, Nevola, Riccardo, additional, Lupia, Tommaso, additional, Rosato, Valerio, additional, Morbiducci, Valeria, additional, Luzzitelli, Ilaria, additional, Sozio, Federica, additional, Di Stefano, Marco, additional, Ciraci, Emanuela, additional, Bulla, Fabio, additional, Guarisco, Riccardo, additional, Cangiano, Cecilia, additional, Imparato, Michele, additional, Maggi, Paolo, additional, Ascione, Antonio, additional, Craxì, Antonio, additional, and Izzi, Antonio, additional

Published
2021
Full Text
View/download PDF

26. OS-036 - Efficacy and safety of lusutrombopag in a real-world Italian series of cirrhotic patients with severe thrombocytopenia undergoing invasive procedures: the Reality study

Author

Gallo, Paolo, De Vincentis, Antonio, Palitti, Valeria Pace, Russello, Maurizio, Vignone, Anthony, Alvaro, Domenico, Tortora, Raffaella, Biolato, Marco, Pompili, Maurizio, Calvaruso, Vincenza, Veneziano, Marzia, Rosato, Valerio, Claar, Ernesto, Villani, Rosanna, Izzi, Antonio, Cozzolongo, Raffaele, Distefano, Marco, Messina, Vincenzo, Ragone, Enrico, Sacco, Rodolfo, Cacciatore, Pierluigi, Moretti, Alessandra, Terracciani, Francesca, Picardi, Antonio, and Gentilucci, Umberto Vespasiani

Published
2023
Full Text
View/download PDF

27. Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study

Author

Messina, Vincenzo, primary, Onorato, Lorenzo, additional, Di Caprio, Giovanni, additional, Claar, Ernesto, additional, Iovinella, Vincenzo, additional, Russo, Antonio, additional, Rosato, Valerio, additional, Salzillo, Angela, additional, Nevola, Riccardo, additional, Simeone, Filomena, additional, Curcio, Fabio, additional, Pisaturo, Mariantonietta, additional, and Coppola, Nicola, additional

Published
2020
Full Text
View/download PDF

28. Effectiveness of new generation DAAs for HCV infection in a large cohort of Italian people who use drugs (PWID): the cleo-grecas real-world experience

Author

Messina, Vincenzo, primary, Iovinella, Vincenzo, additional, Claar, Ernesto, additional, Rosato, Valerio, additional, De Luca, Massimo, additional, Barbarini, Giorgio, additional, Cariti, Giuseppe, additional, Lupia, Tommaso, additional, Quartini, Mariano, additional, D’Offizi, Gianpiero, additional, Luzzitelli, Ilaria, additional, Parruti, Giustino, additional, Sozio, Federica, additional, Scifo, Gaetano, additional, Distefano, Marco, additional, Paolo, Tundo, additional, Benanti, Francesco, additional, Cosco, Lucio, additional, Bulla, Fabio, additional, Gimignani, Giancarlo, additional, Di Rosolini, Maria Antonietta, additional, Palitti, Valeria Pace, additional, Gentilucci, Umberto Vespasiani, additional, Ascione, Antonio, additional, Imparato, Michele, additional, Rinaldi, Luca, additional, Nevola, Riccardo, additional, Di Marco, Vito, additional, Craxì, Antonio, additional, Morbiducci, Valeria, additional, Di Lorenzo, Francesco, additional, Guarisco, Riccardo, additional, Sacco, Rodolfo, additional, and Izzi, Antonio, additional

Published
2020
Full Text
View/download PDF

29. Virological patterns of HCV-patients with failure to second generation direct-acting antivirals

Author

Occhiello, Laura, primary, Starace, Mario, additional, Pisaturo, Mariantonietta, additional, Minichini, Carmine, additional, de Pascalis, Stefania, additional, Macera, Margherita, additional, di Fraia, Alessandra, additional, Alessio, Loredana, additional, Messina, Vincenzo, additional, Claar, Ernesto, additional, Ascione, Tiziana, additional, Marrone, Aldo, additional, Gentile, Ivan, additional, D’Adamo, Giuseppe, additional, Gaeta, Giovanni Battista, additional, and Coppola, Nicola, additional

Published
2020
Full Text
View/download PDF

30. Long-term evaluation of liver stiffness in HCV patients after sustained virological response to DAAs: predictive factors for disease improvement and hepatocellular carcinoma development

Author

Nevola, Riccardo, primary, Rosato, Valerio, additional, Claar, Ernesto, additional, Coppola, Carmine, additional, fontanella, luca, additional, Fracanzani, Anna Ludovica, additional, Piai, Guido, additional, Valente, Giovanna, additional, Ascione, Antonio, additional, Lombardi, Rosa, additional, Saturnino, Mariarosaria, additional, Staiano, Laura, additional, Perillo, Pasquale, additional, Pafundi, Pia Clara, additional, Marrone, Aldo, additional, Sasso, Ferdinando Carlo, additional, Adinolfi, Luigi Elio, additional, and Rinaldi, Luca, additional

Published
2020
Full Text
View/download PDF

31. Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients

Author

Gerussi, Alessio, primary, Rigamonti, Cristina, additional, Elia, Chiara, additional, Cazzagon, Nora, additional, Floreani, Annarosa, additional, Pozzi, Roberta, additional, Pozzoni, Pietro, additional, Claar, Ernesto, additional, Pasulo, Luisa, additional, Fagiuoli, Stefano, additional, Cristoferi, Laura, additional, Carbone, Marco, additional, and Invernizzi, Pietro, additional

Published
2020
Full Text
View/download PDF

32. Unusual liver‐related heart injury

Author

Nevola, Riccardo, primary, Rosato, Valerio, additional, Perillo, Pasquale, additional, Esposito, Nicolino, additional, Massa, Domenico, additional, Frascino, Anna Maria, additional, Capurro, Vittorio, additional, and Claar, Ernesto, additional

Published
2020
Full Text
View/download PDF

33. Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study.

Author

Rosato, Valerio, Ascione, Antonio, Nevola, Riccardo, Fracanzani, Anna Ludovica, Piai, Guido, Messina, Vincenzo, Claar, Ernesto, Coppola, Carmine, Fontanella, Luca, Lombardi, Rosa, Staiano, Laura, Valente, Giovanna, Fascione, Maria Chiara, Giorgione, Chiara, Mazzocca, Annalisa, Galiero, Raffaele, Perillo, Pasquale, Marrone, Aldo, Sasso, Ferdinando Carlo, and Adinolfi, Luigi Elio

Subjects
FATTY liver, LONGITUDINAL method, LIVER, RECEIVER operating characteristic curves, MULTIVARIATE analysis, HEPATITIS C, LONG-term care facilities
Abstract

The long‐term changes of liver stiffness (LS) in patients who achieve viral clearance after direct‐acting anti‐HCV therapy remain undefined. We conducted a multicentre prospective study to investigate this aspect. Patients with HCV infection treated with DAAs were enrolled from six Italian centres; they underwent clinical, biochemical, ultrasound and transient elastography evaluations before treatment (T0), 12 weeks (SVR12) and 24 months (T24) after the end of therapy. Among the 516 consecutive patients enrolled, 301 had cirrhosis. LS significantly decreased from T0 to SVR (14.3 vs 11.1 kPa, p =.002), with a progressive reduction until T24 (8.7 kPa, p <.001). However, only patients with steatosis and those who developed HCC did not experience a late improvement in LS. Multivariate analysis of baseline and follow‐up variables identified steatosis as the only independent predictor of failure of LS improvement (OR 1.802, p =.013). ROC curve analysis of the association of LS with the risk of developing HCC showed that SVR12 ≥14.0 kPa had the highest accuracy (sensitivity 82%, specificity 99%; AUC: 0.774). Multivariate analysis revealed that LS was the only variable independently associated with an increased risk of developing HCC (OR 6.470, p =.035). Achieving an SVR was associated with a progressive, long‐term decline of LS, suggesting a late improvement in liver fibrosis, besides the resolution of inflammation. Fatty liver and the development of HCC interfered with late reduction of LS. Patients with an LS ≥14 kPa at 12 weeks after the end of treatment were at higher risk for developing HCC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study

Author

Persico, Marcello, primary, Aglitti, Andrea, additional, Milella, Michele, additional, Coppola, Carmine, additional, Messina, Vincenzo, additional, Claar, Ernesto, additional, Gentile, Ivan, additional, Sogari, Fernando, additional, Pierri, Paola, additional, Surace, Lorenzo A., additional, Morisco, Filomena, additional, Tundo, Paolo, additional, Brancaccio, Giuseppina, additional, Serviddio, Gaetano, additional, Gatti, Pietro, additional, Termite, Antonio P., additional, Di Costanzo, Giovan G., additional, Caroleo, Benedetto, additional, Cozzolongo, Raffaele, additional, Coppola, Nicola, additional, Longo, Annamaria, additional, Fontanella, Luca, additional, Federico, Alessandro, additional, Rosato, Valerio, additional, Terrenato, Irene, additional, and Masarone, Mario, additional

Published
2019
Full Text
View/download PDF

36. FRI-067-Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database

Author

Gentilucci, Umberto Vespasiani, primary, Rosina, Floriano, additional, Chessa, Luchino, additional, Palitti, Valeria Pace, additional, Picardi, Antonio, additional, Barlattani, Michela, additional, Barlattani, Angelo, additional, Feletti, Valentina, additional, Musetto, Alessandro, additional, Zolfino, Teresa, additional, russello, maurizio, additional, Cannavo, Maria rita, additional, Cozzolongo, Raffaele, additional, Losito, Francesco, additional, Garrucciu, Giovanni, additional, Niro, Grazia, additional, Fontana, Rosanna, additional, Bacca, Donato, additional, Cardinale, Giada, additional, Grasso, Alessandro, additional, Storato, Silvia, additional, Bertino, Gaetano, additional, Frazzetto, Evelise, additional, Scifo, Gaetano, additional, D’adamo, Giuseppe, additional, Fimiani, Basilio, additional, Sacco, Rodolfo, additional, Ricchiuti, Angelo, additional, Ascione, Antonio, additional, Paolo, Tundo, additional, Distefano, Marco, additional, Tarquini, Pierluigi, additional, Marrone, Aldo, additional, Bardon, Valeria, additional, Candilo, Francesco Di, additional, Francavilla, Ruggiero, additional, Madonia, Salvatore, additional, Claar, Ernesto, additional, Adinolfi, Luigi Elio, additional, Puoti, Claudio, additional, Mazziotti, Raffaele, additional, Ubalducci, Giuseppina, additional, D’antò, Maria, additional, Clementi, Carlo, additional, Pellicelli, Adriano, additional, and Izzi, Antonio, additional

Published
2019
Full Text
View/download PDF

37. THU-122-Sofosbuvir/velpatasvir ± ribavirin for retreatment of patients with chronic hepatitis C virus infection and advanced fibrosis failing to a previous DAA combination regimen

Author

Brancaccio, Giuseppina, primary, Martini, Silvia, additional, Ciancio, Alessia, additional, Volpes, Riccardo, additional, Distefano, Marco, additional, Masarone, Mario, additional, Messina, Vincenzo, additional, Montineri, Arturo, additional, Brillanti, Stefano, additional, Biolato, Marco, additional, Dell’isola, Chiara, additional, Lionetti, Raffaella, additional, Montalbano, Marzia, additional, Picciotto, Antonino, additional, Sollima, Salvatore, additional, Taibi, Chiara, additional, Teti, Elisabetta, additional, Ucciferri, Claudio, additional, Claar, Ernesto, additional, Cirillo, Paolo, additional, and Gaeta, Giovanni Battista, additional

Published
2019
Full Text
View/download PDF

38. Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment

Author

Pisaturo, Mariantonietta, primary, Starace, Mario, additional, Minichini, Carmine, additional, De Pascalis, Stefania, additional, Macera, Margherita, additional, Occhiello, Laura, additional, Messina, Vincenzo, additional, Sangiovanni, Vincenzo, additional, Claar, Ernesto, additional, Precone, Davide, additional, Stornaiuolo, Gianfranca, additional, Stanzione, Maria, additional, Gentile, Ivan, additional, Brancaccio, Giuseppina, additional, Martini, Salvatore, additional, Masiello, Addolorata, additional, Megna, Angelo Salomone, additional, Coppola, Carmine, additional, Federico, Alessandro, additional, Sagnelli, Evangelista, additional, Persico, Marcello, additional, Lanza, Alfonso Galeota, additional, Marrone, Aldo, additional, Gaeta, Giovanni Battista, additional, and Coppola, Nicola, additional

Published
2019
Full Text
View/download PDF

39. Virological patterns of HCV patients with failure to interferon‐free regimens

Author

Starace, Mario, primary, Minichini, Carmine, additional, De Pascalis, Stefania, additional, Macera, Margherita, additional, Occhiello, Laura, additional, Messina, Vincenzo, additional, Sangiovanni, Vincenzo, additional, Adinolfi, Luigi E., additional, Claar, Ernesto, additional, Precone, Davide, additional, Stornaiuolo, Gianfranca, additional, Stanzione, Maria, additional, Ascione, Tiziana, additional, Caroprese, Mara, additional, Zampino, Rosa, additional, Parrilli, Gianpaolo, additional, Gentile, Ivan, additional, Brancaccio, Giuseppina, additional, Iovinella, Vincenzo, additional, Martini, Salvatore, additional, Masarone, Mario, additional, Fontanella, Luca, additional, Masiello, Addolorata, additional, Sagnelli, Evangelista, additional, Punzi, Rodolfo, additional, Salomone Megna, Angelo, additional, Santoro, Renato, additional, Gaeta, Giovanni B., additional, and Coppola, Nicola, additional

Published
2018
Full Text
View/download PDF

40. Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis

Author

Persico, Marcello, primary, Rosato, Valerio, additional, Aglitti, Andrea, additional, Precone, Davide, additional, Corrado, Mariano, additional, Luna, Antonio De, additional, Morisco, Filomena, additional, Camera, Silvia, additional, Federico, Alessandro, additional, Dallio, Marcello, additional, Claar, Ernesto, additional, Caporaso, Nicola, additional, and Masarone, Mario, additional

Published
2017
Full Text
View/download PDF

41. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.

Author

Vespasiani-Gentilucci, Umberto, Rosina, Floriano, Pace-Palitti, Valeria, Sacco, Rodolfo, Pellicelli, Adriano, Chessa, Luchino, De Vincentis, Antonio, Barlattani, Michela, Barlattani, Angelo, Feletti, Valentina, Mussetto, Alessandro, Zolfino, Teresa, Russello, Maurizio, Cozzolongo, Raffaele, Garrucciu, Giovanni, Niro, Grazia, Bacca, Donato, Bertino, Gaetano, Claar, Ernesto, and Ascione, Antonio

Subjects
CHOLANGITIS, URSODEOXYCHOLIC acid, ALKALINE phosphatase, CHRONIC active hepatitis, LIVER diseases, AUTOIMMUNE diseases
Abstract

Background and aim: Response to ursodeoxycholic acid (UDCA) is crucial for the prediction of primary biliary cholangitis (PBC) prognosis, and different response criteria were validated and proposed by reference centers for PBC. To date, rates of non-response to UDCA from real-world series are lacking. Methods: Hepatology/Gastroenterology centers belonging to 'Club Epatologi Ospedalieri' (CLEO) and 'Associazione Italiana Gastroenterologi Ospedalieri' (AIGO) were invited to participate in the study, and asked to extract all patients followed for PBC, without any selection or exclusion, and fill in the database provided. Results: Thirty-four centers were enrolled throughout Italy, for a total of 713 patients. None of these centers, except one, had a hepatology outpatient clinic devoted to the care of patients with autoimmune liver diseases. After excluding 79 cases of PBC/autoimmune hepatitis overlaps, 634 patients were analyzed: mean age, 64.4 ± 12.0 years; 91.2% females; F/M 10.3/1. For patients with at least 1 year of UDCA treatment (583), rates of non-response to UDCA were evaluated according to the Paris-I/-II, Toronto and GLOBE criteria, and compared with those in the original cohorts: 27% vs 39% in Paris-I cohort; 39.6% vs 52% in Paris-II; 20.1% vs 43.5% in Toronto; 15.7% vs 30% in GLOBE (age-specific cutoffs). Mean alkaline phosphatase levels on UDCA treatment, and the age-adjusted prevalence of F3/F4 fibrosis, appeared lower in this PBC population than in reference cohorts. Conclusions: A mean ∼15% better response to UDCA is observed in a real-world PBC population, probably due to migration of some of most severe/advanced cases to PBC referral centers. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

42. Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based “Triple Therapy” Experience in Southern Italy

Author

Morisco, Filomena, primary, Masarone, Mario, additional, Rosato, Valerio, additional, Camera, Silvia, additional, Granata, Rocco, additional, Tartaglione, Maria, additional, Coppola, Carmine, additional, Coppola, Nicola, additional, Salomone-Megna, Angelo, additional, Gentile, Ivan, additional, Luna, Antonio, additional, Federico, Alessandro, additional, Precone, Davide, additional, Claar, Ernesto, additional, Abenavoli, Ludovico, additional, and Persico, Marcello, additional

Published
2016
Full Text
View/download PDF

44. Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis

Author

Persico, Marcello, Rosato, Valerio, Aglitti, Andrea, Precone, Davide, Corrado, Mariano, Luna, Antonio De, Morisco, Filomena, Camera, Silvia, Federico, Alessandro, Dallio, Marcello, Claar, Ernesto, Caporaso, Nicola, and Masarone, Mario

Abstract

Background Direct antiviral agents (DAA) demonstrated high efficacy among HCV-infected patients in registered trials. Nevertheless, the impact of these therapies on liver stiffness measurement (LSM) and liver functionality in ‘real-life’ is not well-known. The aim of the present study was to evaluate the sustained virological response (SVR) impact on LSM and clinical parameters of DAA-therapy on a real-life population of HCV patients with F3/F4 fibrosis.Methods A total of 749 HCV genotype 1–4 patients with F3/F4 hepatitis undergoing antiviral therapy were consecutively enrolled in four centres of hepatology in Italy. Clinical, biochemical and imaging data were collected at the baseline (T0), at the end of treatment (EoT) and after 12 weeks (SVR12).Results Out of 749 patients, 69.7% were F4 and 30.3% were F3. SVR12 was reached in 97.5%. LSM significantly decreased from T0 to EoT (P<0.001), whereas, it did not from EoT to SVR12 (P= not significant). Moreover, in F4 no significant differences were found in Child and MELD between T0, EoT and SVR12 (P= not significant). At the univariate analysis of clinical and liver parameters, baseline high glucose (P<0.005), type 2 diabetes (P<0.001), low alanine aminotransferase (ALT; P<0.001), low platelets (P<0.005), and the presence of esophageal varices (EV; P<0.001) were found to be associated with a lack of a significant EoT LSM improvement. At multiple regression, ALT (P<0.05), diabetes (P<0.005) and EV (P<0.05) were inversely associated with significant LSM reduction.Conclusions Virological response to DAA is associated with fibrosis regression and recovery of liver functionality and this can be detected as early as EoT. HCV eradication is associated with a rapid and significant clinical improvement that lasts over time and seems to be negatively influenced by diabetes and EV.

Published
2018
Full Text
View/download PDF

45. Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study.

Author

Messina, Vincenzo, Onorato, Lorenzo, Di Caprio, Giovanni, Claar, Ernesto, Iovinella, Vincenzo, Russo, Antonio, Rosato, Valerio, Salzillo, Angela, Nevola, Riccardo, Simeone, Filomena, Curcio, Fabio, Pisaturo, Mariantonietta, and Coppola, Nicola

Subjects
RIBAVIRIN, HEPATITIS C virus
Abstract

Background: We aimed to evaluate the factors associated with a virological response in a cohort of Hepatitis C virus (HCV)-infected people who inject drugs (PWID) treated with direct acting antivirals (DAAs). Methods: We conducted a multicenter retrospective cohort study enrolling HCV-infected PWID treated with DAAs. The primary outcome evaluated was the sustained virological response (SVR12) rate. Results: Five hundred and twenty HCV-infected PWID treated with all-oral DAA-based regimens were enrolled; a total of 168 (32.3%) patients presented genotype 1a, 109 (21.0%) genotype 1b, and 174 (33.5%) genotype 3; a total 152 of the 520 subjects (29.2%) were cirrhotics; a total 118 (22.7%) and 373 (71.7%) were treated with DAA regimens of second and third generation, respectively; a total 169 (33.6%) patients were receiving an opioid agonist at the start of antiviral therapy. Only 11 subjects (2.1%) did not show an SVR12. A significant correlation was found between treatment with opioid substitution therapy (p < 0.001), Human Immunodeficiency Virus (HIV) coinfection (p = 0.002), and treatment with first- or second-generation regimens (p = 0.0015) and HCV failure. Upon multivariate analysis, treatment with a first- or second-generation DAA was the only factor independently associated with failure (OR 10.4, 95% CI: 1.43 to 76.1, p = 0.02). Conclusions: Treatment with DAAs led to a high SVR12 rate (97.9%) in a large cohort of HCV-infected PWID. The only predictor of viral failure found in our analysis was treatment with first- and second-generation DAA. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. PREDICTION OF LIVER FAILURE IN CIRRHOTIC PRIMARY BILIARY CHOLANGITIS PATIENTS UNDER OBETICHOLIC ACID

Author

Vincentis, Antonio, D Amato, Daphne, Vigano, Mauro, Marzioni, Marco, Giannini, Edoardo G., Pompili, Maurizio, Cazzagon, Nora, Muratori, Luigi, Ana LLEO, Calvaruso, Vincenza, Marconi, Giulia, Degasperi, Elisabetta, Abenavoli, Ludovico, Brunetto, Maurizia R., Vanni, Ester, Colapietro, Francesca, Pellicano, Rinaldo, Romana Ponziani, Francesca, Labanca, Sara, Morgando, Anna, Coco, Barbara, Galati, Giovanni, Morelli, Olivia, Cannavo, Mariarita, Chessa, Luchino, Cuccorese, Giuseppe, Russello, Maurizio, Di Stefano, Marco, Cozzolongo, Raffaele, D Anto, Maria, Scifo, Gaetano, Palitti, Valeria Pace, Fontana, Rossana, Niro, Grazia Anna, Rosina, Floriano, Pellicelli, Adriano, Sacco, Rodolfo, Saitta, Carlo, Fiorini, Cecilia, Zolfino, Teresa, Storato, Silvia, Simone, Loredana, Marra, Fabio, Picardi, Antonio, Invernizzi, Pietro, Claar, Ernesto, Izzi, Antonio, Vespasiani-Gentilucci, Umberto, and Carbone, Marco

47. FRI454 - Long-term evaluation of liver stiffness in HCV patients after sustained virological response to DAAs: predictive factors for disease improvement and hepatocellular carcinoma development.

Author

Nevola, Riccardo, Rosato, Valerio, Claar, Ernesto, Coppola, Carmine, fontanella, luca, Fracanzani, Anna Ludovica, Piai, Guido, Valente, Giovanna, Ascione, Antonio, Lombardi, Rosa, Saturnino, Mariarosaria, Staiano, Laura, Perillo, Pasquale, Pafundi, Pia Clara, Marrone, Aldo, Sasso, Ferdinando Carlo, Adinolfi, Luigi Elio, and Rinaldi, Luca

Subjects
*LIVER, *HEPATOLOGY, *VIRAL hepatitis, *HEPATITIS C
Published
2020
Full Text
View/download PDF

48. THU454 - Effectiveness of new generation DAAs for HCV infection in a large cohort of Italian people who use drugs (PWID): the cleo-grecas real-world experience.

Author

Messina, Vincenzo, Iovinella, Vincenzo, Claar, Ernesto, Rosato, Valerio, De Luca, Massimo, Barbarini, Giorgio, Cariti, Giuseppe, Lupia, Tommaso, Quartini, Mariano, D'Offizi, Gianpiero, Luzzitelli, Ilaria, Parruti, Giustino, Sozio, Federica, Scifo, Gaetano, Distefano, Marco, Paolo, Tundo, Benanti, Francesco, Cosco, Lucio, Bulla, Fabio, and Gimignani, Giancarlo

Subjects
*ITALIANS, *DRUG abuse, *INFECTION, *VIRAL hepatitis, *HEPATITIS C
Published
2020
Full Text
View/download PDF

49. Predictors of early and late hepatocellular carcinoma recurrence

Author

Riccardo Nevola, Rachele Ruocco, Livio Criscuolo, Angela Villani, Maria Alfano, Domenico Beccia, Simona Imbriani, Ernesto Claar, Domenico Cozzolino, Ferdinando Carlo Sasso, Aldo Marrone, Luigi Elio Adinolfi, Luca Rinaldi, Nevola, Riccardo, Ruocco, Rachele, Criscuolo, Livio, Villani, Angela, Alfano, Maria, Beccia, Domenico, Imbriani, Simona, Claar, Ernesto, Cozzolino, Domenico, Sasso, Ferdinando Carlo, Marrone, Aldo, Adinolfi, Luigi Elio, and Rinaldi, Luca

Subjects
Liver resection, Early recurrence, Hepatocellular carcinoma, Gastroenterology, Late recurrence, General Medicine, Liver transplant, Thermal ablation, Predictor
Abstract

Hepatocellular carcinoma (HCC) is the most frequent liver neoplasm, and its incidence rates are constantly increasing. Despite the availability of potentially curative treatments (liver transplantation, surgical resection, thermal ablation), long-term outcomes are affected by a high recurrence rate (up to 70% of cases 5 years after treatment). HCC recurrence within 2 years of treatment is defined as "early" and is generally caused by the occult intrahepatic spread of the primary neoplasm and related to the tumor burden. A recurrence that occurs after 2 years of treatment is defined as "late" and is related to de novo HCC, independent of the primary neoplasm. Early HCC recurrence has a significantly poorer prognosis and outcome than late recurrence. Different pathogenesis corresponds to different predictors of the risk of early or late recurrence. An adequate knowledge of predictive factors and recurrence risk stratification guides the therapeutic strategy and post-treatment surveillance. Patients at high risk of HCC recurrence should be referred to treatments with the lowest recurrence rate and when standardized to combined or adjuvant therapy regimens. This review aimed to expose the recurrence predictors and examine the differences between predictors of early and late recurrence.

Published
2023

50. Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study

Author

Chiara Giorgione, Carmine Coppola, Riccardo Nevola, Vincenzo Messina, Ferdinando Carlo Sasso, Laura Staiano, Rosa Lombardi, Luigi Elio Adinolfi, Annalisa Mazzocca, Antonio Ascione, Luca Rinaldi, Pasquale Perillo, Ernesto Claar, Raffaele Galiero, M.C. Fascione, Valerio Rosato, Anna Ludovica Fracanzani, Giovanna Valente, Aldo Marrone, Guido Piai, Luca Fontanella, Rosato, Valerio, Ascione, Antonio, Nevola, Riccardo, Fracanzani, Anna Ludovica, Piai, Guido, Messina, Vincenzo, Claar, Ernesto, Coppola, Carmine, Fontanella, Luca, Lombardi, Rosa, Staiano, Laura, Valente, Giovanna, Fascione, Maria Chiara, Giorgione, Chiara, Mazzocca, Annalisa, Galiero, Raffaele, Perillo, Pasquale, Marrone, Aldo, Sasso, Ferdinando Carlo, Adinolfi, Luigi Elio, and Rinaldi, Luca

Subjects
Liver Cirrhosis, medicine.medical_specialty, Carcinoma, Hepatocellular, Cirrhosis, Multivariate analysis, Antiviral Agents, Gastroenterology, Virology, Internal medicine, Humans, Medicine, Prospective Studies, Prospective cohort study, Antiviral Treatment, Hepatology, business.industry, Liver Neoplasms, Fatty liver, Hepatocellular Carcinoma, Hepatitis C, medicine.disease, Liver Stiffness, Infectious Diseases, Liver, Hepatocellular carcinoma, Elasticity Imaging Techniques, Steatosis, business, Transient elastography
Abstract

The long-term changes of liver stiffness (LS) in patients who achieve viral clearance after direct-acting anti-HCV therapy remain undefined. We conducted a multicenter prospective study to investigate this aspect. Patients with HCV infection treated with DAAs were enrolled from six Italian centers; they underwent clinical, biochemical, ultrasound, and transient elastography evaluations before treatment (T0), 12 weeks (SVR12), and 24 months (T24) after the end of therapy. Among the 516 consecutive patients enrolled, 301 had cirrhosis. LS significantly decreased from T0 to SVR (14.3 kPa vs 11.1 kPa, p=0.002), with a progressive reduction until T24 (8.7 kPa, p

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results